Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > Integrin alpha V beta 6 > CHEK-ATP125

HEK293/Human Integrin alpha V beta 6 Stable Cell Line

Order Now

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Description
    HEK293/Human Integrin alpha V beta 6 Stable Cell Line
  • Application

    • Useful for cell-based Integrin alpha V beta 6 binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
  • Background
    Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message